News

Protagenic Therapeutics (PTIX) Stock Soars 240% On Phytanix Merger
Protagenic Therapeutics shares soared 240% Monday on its all-stock merger with Phytanix Bio. New Phytanix targets CNS disorders with an expanded diverse pipeline and experienced team.
Rolling Out31m
Common causes of partial paralysis you should know
Discover the major causes of partial paralysis from stroke and trauma to inflammatory conditions and tumors, plus warning ...
SK Life Science Launches Its Second National Ad, Continuing to Lead with the Only Direct-to-Consumer Commercial for an Anti-Seizure Drug in the U.S.
SK Life Science, Inc., a global leader in developing treatments for central nervous system (CNS) disorders and a subsidiary ...
Arbor Biotechnologies Appoints Don Haut, Ph.D., as Chief Business Officer
Seasoned biopharma executive brings more than twenty years of business development, strategy, and operational expertise to ...
Investing Snacks4h
Lilly Hears Opportunity in $1.3B RNA Therapy Deal
Eli Lilly is turning up the volume on gene therapy with a $1.3 billion partnership with Rznomics to tackle sensorineural ...